VA-HEALTHWARE/DTA
The Digital Therapeutics Alliance (DTA) and Healthware Group today announced a partnership to form a coalition convening thought leaders, policymakers, and professional and trade associations from across the European region to discuss and develop harmonised pathways for the recognition and scalability of digital therapeutics (DTx) at the local, national, and regional levels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614005168/en/
Developing this pan-European coalition will be a catalysing factor for the successful scaling of DTx therapies across countries. The first in-person meeting of the coalition will take place at Frontiers Health Global Conference this coming October in Milan, Italy. The coalition will focus on co-creating a vision for the future by analysing existing frameworks and infrastructure, sharing learnings, and developing recommendations to build an environment which ensures safe and effective DTx therapies can be accessible to patients regardless of where they live.
The partnership between Healthware and DTA is part of the Alliance’s Resource Partner program, a best-in-class network of leading experts in the rapidly evolving DTx industry who collaborate with DTA members to develop resources to advance digital therapeutics to transform global healthcare. Through this relationship, Healthware will also support DTA’s Europe Policy Task Group, which is focused on understanding and informing key aspects of the European policy landscape, including Health Technology Assessment frameworks, national funding, clinician engagement, and patient access and reimbursement pathways.
This announcement follows a longstanding collaboration between the two organisations, which began with DTA’s European launch at the Frontiers Health Global Conference in 2017. The development of a pan-European coalition will deepen DTA’s presence in the region and further its mission to broaden the understanding, adoption, and integration of clinically evaluated digital therapeutics into healthcare through education, advocacy, and cross-industry collaboration.
Healthware brings over a decade of experience and advocacy of digital health/digital therapeutics and an even longer history of developing digitally focused solutions for life sciences, payors and medical device companies. Healthware has also developed a corporate investment fund to support and invest in digital health companies and nurtures a vast digital health network and expertise. In the area of digital therapeutics specifically, Healthware Group supports both the research and development of DTx products as well as the go to market, access, system integration and adoption strategies in partnership with pharmaceutical companies, digital health and DTx companies and all ecosystem stakeholders.
“We have been partnering with Healthware since the inception of DTA and are thrilled to have their knowledge and expertise on board,” shared Megan Coder, DTA Chief Policy Officer. “As we jointly develop this coalition, our aim is to enable full scale access to digital therapeutics throughout Europe to transform critical aspects of patient care.”
Roberto Ascione , CEO of Healthware Group says, “My team at Healthware has been helping shape the digital health landscape in Europe for many years, through our work with Frontiers Health and in direct support of our clients. We are excited to deepen our partnership with DTA to help shape the European policy landscape and ensure DTx companies can scale. We are huge advocates for the positive impact digital therapeutics can have on patients and believe that these solutions can help fill care gaps, augment care delivery and most importantly support patients in novel ways.”
Healthware and DTA look forward to building this coalition together and are seeking the active participation of key stakeholders across the region. Further announcements about the coalition and how to get involved will be rolling out soon.
* * *
Healthware Group
Healthware Group is a global health innovation and technology leader providing transformational advisory and technology services for commercial, medical, and R&D operations of life-sciences and digital health companies, combined with design and development of digital medicines and digital therapeutics products.
Proprietary software platforms, specialised media and educational assets as well as a corporate venturing arm, ensure accelerated product development, close integration within the innovation ecosystem, continuous pipeline development and superior market access capabilities.
Founded in Italy in 1997 by CEO and digital health pioneer Roberto Ascione, Healthware Group encompasses several vertical brands, including flagship commercial and medical communications agency Healthware International, media consultancy Healthware Engage, innovation consultancy Healthware Labs, and creative motion lab & virtual hybrid events specialist SWM and the digital therapeutics R&D partner and product portfolio organisation, Healthware Therapeutics.
It also operates Healthware Ventures, the corporate investment arm that supports digital health start-ups with a focus on digital therapeutics and telehealth and is the co-host of the global leading digital health conference Frontiers Health.
Healthware has a team of 200+ professionals with main offices in Salerno, London, New York, Milan, Helsinki and, together with its joint venture partner Intouch Group, has a combined reach of 1,500+ people in over 15 offices in Europe, the US, and Asia.
Thanks to the Argon Global Healthcare acquisition, the group also runs the Healthware Global Network, one of the largest international networks of independent healthcare agencies covering 25 Countries worldwide.
Healthware Group is privately owned and backed by FITEC, a leading European VC fund focusing on technology.
For more information, please visit healthwaregroup.com
and follow us on LinkedIn
and Twitter.
Digital Therapeutics Alliance
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org or follow us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005168/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Valeo Foods Group Recognised for Sustainability Leadership with EcoVadis Platinum Medal20.10.2025 09:00:00 CEST | Press release
Valeo Foods Group, one of Europe's leading producers of quality sweets, treats and snacks has been awarded a Platinum Medal, the highest recognition level, in the EcoVadis sustainability assessment. Valeo Foods now ranks among the top one percent of companies evaluated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020547491/en/ Valeo Foods Group recognised for sustainability leadership with EcoVadis Platinum Medal. Ronald Kers, Valeo Foods Group CEO said “Achieving EcoVadis Platinum rating is a proud moment for our business. It reflects the dedication of our people and our determination to integrate sustainability into everything we do – from how we source and produce, to how we support communities and protect the planet.” Dr Grainne O’Halloran, Head of Sustainability at Valeo Foods added: “We are incredibly proud to have achieved EcoVadis Platinum Medal this year. Our increased score reflects our ongoing commitment to
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage20.10.2025 08:00:00 CEST | Press release
Lazard, Inc. (NYSE: LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the European Financial Sponsors Coverage. He will report to Klaus H. Hessberger, Global Co-Head and Head of Europe for Lazard’s Financial Sponsors Group, to further strengthen the firm’s presence and partnerships with financial sponsors across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019307537/en/ Edouard Panié Mr. Panié joins from Goldman Sachs, where he was a Managing Director for nearly two decades, advising on more than 60 landmark M&A, debt, and equity transactions for leading alternative asset managers in private equity, growth equity, and infrastructure, as well as entrepreneurs, families, and corporates. “Private capital is playing an increasingly pivotal role in shaping industries and driving growth. Edouard’s extensive experience and relationships will strengthen Lazard’s ability to pro
Lone Star Announces Sale of Xella to Holcim20.10.2025 06:40:00 CEST | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund X, LP of a binding agreement to sell Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. The transaction values Xella at approximately €1.85 billion. Headquartered in Duisburg, Germany, Xella is a European provider of efficient and sustainable walling solutions for the entire house shell, operating brands such as Ytong, Silka, Hebel and Multipor. The company employs more than 4,000 team members. In partnership with Lone Star, Xella has taken significant strides in recent years to optimize its offering by strategically focusing the business on walling solutions, while also enhancing its commercial and digital capabilities. Under Lone Star’s stewardship, Xella has also continued to progress its sustainability initiatives. Today, the business stands as a market leader in its sector with a strong reputation for a people-first c
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 06:00:00 CEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom